Roberto Ria
Policlinico - Piazza Giulio Cesare, 11 I-70124 BARI
Italy
Review Article
Peripheral Blood Progenitor Cells Mobilization in Patients with Multiple Myeloma
Author(s): Roberto Ria and Angelo Vacca
Roberto Ria and Angelo Vacca
Autologous stem cell transplantation (ASCT) is considered the standard therapy for younger patients with newly diagnosed symptomatic multiple myeloma (MM). The introduction into clinical practice of novel agents (i.e.: proteasome inhibitors and immunomodulatory derivatives [IMiDs]) has significantly contributed to major advances in MM therapy and prognosis. These novel agents are incorporated into induction regimens to enhance the depth of response before ASCT and further improve post-ASCT outcomes. Collection of adequate hematopoietic stem cells (HSCs) is necessary for successful autologous transplantation. The mobilizing regimen usually consists of cyclophosphamide or disease-specific agents, in combination with a hematopoietic cytokine, usually G-CSF, which mobilizes HPSCs into the bloodstream, in particular when administered after myelosuppressive.. View More»
DOI:
10.4172/2157-7633.1000226